Core Insights - Windtree Therapeutics, Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application related to an intravenous formulation of istaroxime for treating acute heart failure [1] - The CEO of Windtree emphasizes the significant impact of acute heart failure on patients and healthcare systems, highlighting the need for innovative drug treatments [1] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions, with a portfolio that includes istaroxime, which is in Phase 2 trials for acute heart failure and cardiogenic shock [3] - Istaroxime is a first-in-class dual-mechanism therapy that aims to enhance both systolic and diastolic cardiac function, showing promising results in improving cardiac function and blood pressure without adverse effects on heart rate [2][3]
Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure